Compare Intel Corp (INTC) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intel Corp vs Novo Nordisk A/S — how do they compare? Intel Corp trades at $105.03 (market cap $487.82B), while Novo Nordisk A/S trades at $49.39 (market cap $220.53B). The key difference: Intel Corp is far larger — about 2.2× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| INTC | NVO | |
|---|---|---|
Market Cap | $487.82B | $220.53B |
Volume | 43,552,012 | — |
Sector | Technology | Health |
52-Week High | $140.94 | $71.70 |
52-Week Low | $19.31 | $35.29 |
Enterprise Value | $500.07B | $239.49B |
Dividend Yield | 2.24% | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $97.87, up 2.97% on the day, with technical indicators showing a bullish overall signal despite mixed moving averages. The company has beaten earnings estimates for three consecutive quarters, though it reported a net loss of -$267 million in 2025. Recent news highlights volatility in semiconductor stocks amid AI-driven market shifts, with Intel expanding its Google Cloud AI partnership to boost enterprise growth.
Intel's outlook is cautiously optimistic, supported by earnings beats and strategic AI initiatives, but risks include intense competition, margin pressures, and sector volatility. The consensus price target of $109.55 suggests potential upside, though investors must weigh financial recovery against technological challenges in a dynamic chip market.
Novo Nordisk (NVO) trades at $49.68, down 1.27% on the day, amid a bullish technical signal from moving averages. The company demonstrates robust fundamentals with a trailing P/E of 12.08 and a net income margin of 37.2%, supported by three consecutive quarterly earnings beats. Recent positive catalysts include EU and Indian regulatory approvals for its oral Wegovy weight-loss pill, expanding its GLP-1 franchise.
The outlook remains positive given strong analyst consensus (57.9% Buy ratings) and projected earnings growth, though risks include intensifying competition in the weight-loss drug market and potential margin pressure. The stock presents a compelling opportunity for investors seeking exposure to a profitable leader in metabolic diseases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
